Comparison of mortality in ESRD patients on convective and diffusive extracorporeal treatments. The Registro Lombardo Dialisi E Trapianto.

BACKGROUND The aim of this study was to evaluate the effect of convective [hemodiafiltration (HDF) or hemofiltration (HF)] versus diffusive treatments [hemodialysis (HD)] on end-stage renal disease (ESRD) patient mortality and dialysis-related amyloidosis (DRA) using data from the Lombardy Registry. METHODS For this purpose, 6, 444 patients (aged 56.4 +/- 15.6 years, females 39.5%, diabetics 10. 6%) who started renal replacement therapy (RRT) on HD, HDF, or HF between 1983 and 1995 were considered. A total of 1,082 patients were treated with HDF or HF (first choice in the case of 188), with a median follow-up of 29.7 months. The median follow-up of the 6,298 patients on HD (first choice in the case of 6256) was 22.4 months. The time of survival on dialysis to carpal tunnel syndrome (CTS) surgery was evaluated as a hard marker of DRA morbidity. Survival was compared by means of the Cox proportional regression hazards model, using CTS surgery and all deaths as events for morbidity and mortality, respectively. Explanatory covariates were age, gender, and comorbidities; dialysis modality was tested as a time-dependent covariate. RESULTS The relative risk (RR) for CTS surgery was significantly higher in older patients [RR = 1.04 per year of age on admission to RRT, 95% confidence interval (CI) 1.02 to 1.06; P = 0. 0001], in diabetics (RR = 2.63, 95% CI 1.30 to 5.31; P = 0.0007), and in patients with heart disease (RR = 5.36, 95% CI 2.27 to 12.68 P = 0.0001). Adjusting for age and diabetic status, the RR for CTS surgery was 42% lower in the patients treated with HDF or HF (RR = 0. 58, 95% CI 0.35 to 0.95, P = 0.03). The RR for mortality, adjusted for age, gender, and comorbidities, was 10% lower in patients treated with HDF or HF (RR = 0.90, 95% CI 0.76 to 1.06; P = NS). CONCLUSION These results support the hypothesis that convective treatments are associated with a nonsignificant trend toward better survival and significantly delay the need for CTS surgery. An older age and the presence of diabetes and heart disease are other important risk factors for CTS surgery. These results could have an important clinical impact given the relevance of DRA in dialysis patient morbidity.

[1]  David Collett.  Modelling Survival Data in Medical Research , 1994 .

[2]  S. Nishi,et al.  Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. , 1997, Kidney international.

[3]  D. Marcelli,et al.  Dialysis patient outcomes in Europe vs the USA. Why do Europeans live longer? , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  J. Ehrich,et al.  Case control study on dialysis arthropathy: the influence of two different dialysis membranes: data from the EDTA Registry. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  M. Galanski,et al.  β2-microglobulin associated amyloidosis: A vanishing complication of long-term hemodialysis? , 1997 .

[6]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[7]  G. Beck,et al.  The Hemodialysis (HEMO) Study: Rationale for Selection of Interventions , 1996 .

[8]  R M Hakim,et al.  The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. , 1996, Journal of the American Society of Nephrology : JASN.

[9]  B. Maldague,et al.  Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. , 1991, Kidney international.

[10]  E. Azoulay,et al.  Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The Co-operative Group on Dialysis-associated Arthropathy. , 1992, British journal of rheumatology.

[11]  M. Jadoul,et al.  Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. , 1994, Kidney international.

[12]  C. Ronco,et al.  Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group. , 1996, Kidney international.

[13]  R. Vanholder,et al.  The Uraemic Syndrome , 1996 .

[14]  W. Owen,et al.  Interaction between β2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis , 1997 .

[15]  J. Crowley,et al.  Covariance Analysis of Heart Transplant Survival Data , 1977 .

[16]  V. Wizemann,et al.  Simultaneous hemofiltration/hemodialysis: an effective alternative to hemofiltration and conventional hemodialysis in the treatment of uremic patients. , 1978, Clinical nephrology.

[17]  M. Jadoul,et al.  Histological prevalence of beta 2-microglobulin amyloidosis in hemodialysis: a prospective post-mortem study. , 1997, Kidney international.

[18]  D. Marcelli,et al.  ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. , 1996, Kidney international.

[19]  V. Bonomini,et al.  Long-Term Comparative Evaluation of Synthetic and Cellulosic Membranes in Dialysis , 1994, The International journal of artificial organs.

[20]  R. Wolfe,et al.  Effect of the dialysis membrane on mortality of chronic hemodialysis patients. , 1996, Kidney international.

[21]  J. Hornberger,et al.  A multivariate analysis of mortality and hospital admissions with high-flux dialysis. , 1992, Journal of the American Society of Nephrology : JASN.

[22]  H. Schiffl,et al.  Beta-2-microglobulin removal by different hemodialysis membranes. , 1995, Contributions to nephrology.

[23]  H. Lehnert,et al.  Prevalence of dialysis-related amyloidosis in diabetic patients. Diabetes Amyloid Study Group. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  F. Gejyo,et al.  Dialysis amyloidosis: current disease concepts and new perspectives for its treatment. , 1990, Contributions to nephrology.

[25]  O. Toupance,et al.  Carpal tunnel syndrome and type of dialysis membrane. , 1989, BMJ.

[26]  B. Charra,et al.  Chronic renal failure treatment duration and mode: their relevance to the late dialysis periarticular syndrome. , 1988, Blood purification.

[27]  F. Locatelli,et al.  Biocompatibility in haemodialysis: fact and fiction , 1997, Current opinion in nephrology and hypertension.

[28]  L. Henderson,et al.  Clinical experience with intermittent hemodiafiltrations. , 1973, Transactions - American Society for Artificial Internal Organs.

[29]  D. Marcelli,et al.  1983 to 1992: report on regular dialysis and transplantation in Lombardy. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  H. Fricke,et al.  High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. , 1996, American journal of nephrology.